Back
Rate this talk
Your peers have not rated this talk yet.
20-minute watch | Talk 1 of 4

CAR T: Improving survival with the SoC in 2L LBCL

Why has CAR T become the SoC in 2L LBCL?

Dr Anna Sureda
SYMPOSIUM
EBMT

Dr Anna Sureda
Institut Català d’Oncologia, Barcelona, Spain

Dr Anna Sureda of the Institut Català d’Oncologia, Barcelona,
Spain reviews clinical trial data and real-world evidence that pave the way to CAR T as SoC in 2L LBCL

Read more

Talks in this series

Dr Anna Sureda presents a symposium
20-minute watch | Talk 1 of 4
CAR T: Improving survival with the SoC in 2L LBCL
Why has CAR T become the SoC in 2L LBCL?
Dr Anna Sureda presents a symposium
20-minute watch
CAR T: Improving survival with the SoC in 2L LBCL

Why has CAR T become the SoC in 2L LBCL?

Dr Wendy Osborne presents a symposium
14-minute watch | Talk 2 of 4
What is the most appropriate treatment choice in 2L LBCL? A case-based approach
Dr Wendy Osborne
Dr Wendy Osborne presents a symposium
14-minute watch

What is the most appropriate treatment choice in 2L LBCL? A case-based approach

Dr Wendy Osborne

Dr Wendy Osborne, Ms Surabhi Chaturvedi, Neil (Patient) present a symposium
14-minute watch | Talk 3 of 4
Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist
Ms Surabhi Chaturvedi, Dr Wendy Osborne
Dr Wendy Osborne, Ms Surabhi Chaturvedi, Neil (Patient) present a symposium
14-minute watch

Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist

Ms Surabhi Chaturvedi, Dr Wendy Osborne

Ms Surabhi Chaturvedi and Dr Suzanne van Dorp present a symposium
24-minute watch | Talk 4 of 4
How can we bring CAR T’s curative potential to more patients?
Ms Surabhi Chaturvedi, Dr Suzanne van Dorp
Ms Surabhi Chaturvedi and Dr Suzanne van Dorp present a symposium
24-minute watch

How can we bring CAR T’s curative potential to more patients?

Ms Surabhi Chaturvedi, Dr Suzanne van Dorp

Dr Anna Sureda presents a symposium
20-minute watch | Talk 1 of 4
CAR T: Improving survival with the SoC in 2L LBCL
Why has CAR T become the SoC in 2L LBCL?
Dr Anna Sureda presents a symposium
20-minute watch
CAR T: Improving survival with the SoC in 2L LBCL

Why has CAR T become the SoC in 2L LBCL?

Dr Wendy Osborne presents a symposium
14-minute watch | Talk 2 of 4
What is the most appropriate treatment choice in 2L LBCL? A case-based approach
Dr Wendy Osborne
Dr Wendy Osborne presents a symposium
14-minute watch

What is the most appropriate treatment choice in 2L LBCL? A case-based approach

Dr Wendy Osborne

Dr Wendy Osborne, Ms Surabhi Chaturvedi, Neil (Patient) present a symposium
14-minute watch | Talk 3 of 4
Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist
Ms Surabhi Chaturvedi, Dr Wendy Osborne
Dr Wendy Osborne, Ms Surabhi Chaturvedi, Neil (Patient) present a symposium
14-minute watch

Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist

Ms Surabhi Chaturvedi, Dr Wendy Osborne

Ms Surabhi Chaturvedi and Dr Suzanne van Dorp present a symposium
24-minute watch | Talk 4 of 4
How can we bring CAR T’s curative potential to more patients?
Ms Surabhi Chaturvedi, Dr Suzanne van Dorp
Ms Surabhi Chaturvedi and Dr Suzanne van Dorp present a symposium
24-minute watch

How can we bring CAR T’s curative potential to more patients?

Ms Surabhi Chaturvedi, Dr Suzanne van Dorp

Interested in this topic?

Find more like this

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.